BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1672381)

  • 1. 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. III. Structurally diverse 5-HT1A partial agonists attenuate mu- but not kappa-opioid antinociception in mice and rats.
    Millan MJ; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):993-1001. PubMed ID: 1672381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner.
    Millan MJ; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):983-92. PubMed ID: 1672380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
    Millan MJ; Bervoets K; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ; Morris BJ; Herz A
    J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1430-8. PubMed ID: 8103794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli.
    Millan MJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):334-41. PubMed ID: 2571722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
    Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
    Roerig SC; Fujimoto JM
    J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of opioid induced antinociception by 5-HT1A partial agonists in the rat.
    Millan MJ; Colpaert FC
    Neuropharmacology; 1990 Mar; 29(3):315-8. PubMed ID: 2139188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
    Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
    Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).
    Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1021-7. PubMed ID: 7680715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors.
    Stein C; Millan MJ; Shippenberg TS; Peter K; Herz A
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1269-75. PubMed ID: 2539460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.